Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

Fig. 3

Drivers of clinical inertia in the management of cardiorenal risk in T2D. We argue that the slow uptake of SGLT2i and GLP-1 RA following CVOT disclosures can be attributed to clinical inertia. We suggest several factors that may be responsible for driving this inertia; each will need to be addressed if we are to ensure that eligible, at-risk patients are to benefit from the risk reductions proven in CVOTs, and now emerging from dedicated HF and renal studies

Back to article page
\